+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder (OAB) Therapeutics - Market Analysis, Trends, and Forecasts

  • ID: 1882057
  • Report
  • 142 Pages
  • Global Industry Analysts, Inc
1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Pfizer, Inc
  • Recordati Spa
  • MORE
The Overactive Bladder (OAB) Therapeutics market worldwide is projected to grow by US$516.4 Million, driven by a compounded growth of 2.2%. Anticholinergic Agents, one of the segments analyzed and sized in this study, displays the potential to grow at over 2.1%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$2.8 Billion by the year 2025, Anticholinergic Agents will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 1.8% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$20.4 Million to the region's size and clout in the next 5 to 6 years. Over US$15.4 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Anticholinergic Agents will reach a market size of US$169.5 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 3.4% over the next couple of years and add approximately US$140.4 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • Allergan PLC
  • Astellas Pharma, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Astellas Pharma, Inc.
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Pfizer, Inc
  • Recordati Spa
  • MORE

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

Overactive Bladder (OAB) Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Overactive Bladder (OAB) Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 2: Overactive Bladder (OAB) Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017

TABLE 3: Overactive Bladder (OAB) Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: Anticholinergic Agents (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 5: Anticholinergic Agents (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 6: Anticholinergic Agents (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Beta-3 Adrenoreceptor Agonists (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025

TABLE 8: Beta-3 Adrenoreceptor Agonists (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017

TABLE 9: Beta-3 Adrenoreceptor Agonists (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Overactive Bladder (OAB) Therapeutics Market Share (in %) by Company: 2019 & 2025

TABLE 10: United States Overactive Bladder (OAB) Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 11: Overactive Bladder (OAB) Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 12: United States Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

CANADA

TABLE 13: Canadian Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 14: Canadian Overactive Bladder (OAB) Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 15: Overactive Bladder (OAB) Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

JAPAN

TABLE 16: Japanese Market for Overactive Bladder (OAB) Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 17: Overactive Bladder (OAB) Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 18: Japanese Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

CHINA

TABLE 19: Chinese Overactive Bladder (OAB) Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 20: Overactive Bladder (OAB) Therapeutics Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017

TABLE 21: Chinese Overactive Bladder (OAB) Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Overactive Bladder (OAB) Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 22: European Overactive Bladder (OAB) Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025

TABLE 23: Overactive Bladder (OAB) Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017

TABLE 24: European Overactive Bladder (OAB) Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 25: European Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 26: Overactive Bladder (OAB) Therapeutics Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 27: European Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

FRANCE

TABLE 28: Overactive Bladder (OAB) Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 29: French Overactive Bladder (OAB) Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 30: French Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

GERMANY

TABLE 31: Overactive Bladder (OAB) Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 32: German Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 33: German Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

ITALY

TABLE 34: Italian Overactive Bladder (OAB) Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 35: Overactive Bladder (OAB) Therapeutics Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017

TABLE 36: Italian Overactive Bladder (OAB) Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 37: United Kingdom Market for Overactive Bladder (OAB) Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 38: Overactive Bladder (OAB) Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 39: United Kingdom Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

SPAIN

TABLE 40: Spanish Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 41: Spanish Overactive Bladder (OAB) Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 42: Overactive Bladder (OAB) Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

RUSSIA

TABLE 43: Russian Overactive Bladder (OAB) Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 44: Overactive Bladder (OAB) Therapeutics Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 45: Russian Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 46: Rest of Europe Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 47: Overactive Bladder (OAB) Therapeutics Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 48: Rest of Europe Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 49: Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 50: Overactive Bladder (OAB) Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017

TABLE 51: Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 52: Overactive Bladder (OAB) Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 53: Asia-Pacific Overactive Bladder (OAB) Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 54: Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 55: Overactive Bladder (OAB) Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 56: Australian Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 57: Australian Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

INDIA

TABLE 58: Indian Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 59: Indian Overactive Bladder (OAB) Therapeutics Historic Market Review by Drug Class in US$ Million: 2009-2017

TABLE 60: Overactive Bladder (OAB) Therapeutics Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

SOUTH KOREA

TABLE 61: Overactive Bladder (OAB) Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 62: South Korean Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 63: Overactive Bladder (OAB) Therapeutics Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 64: Rest of Asia-Pacific Market for Overactive Bladder (OAB) Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 65: Overactive Bladder (OAB) Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 66: Rest of Asia-Pacific Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 67: Latin American Overactive Bladder (OAB) Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025

TABLE 68: Overactive Bladder (OAB) Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 69: Latin American Overactive Bladder (OAB) Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 70: Latin American Overactive Bladder (OAB) Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 71: Overactive Bladder (OAB) Therapeutics Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017

TABLE 72: Latin American Overactive Bladder (OAB) Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 73: Argentinean Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 74: Overactive Bladder (OAB) Therapeutics Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 75: Argentinean Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

BRAZIL

TABLE 76: Overactive Bladder (OAB) Therapeutics Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 77: Brazilian Overactive Bladder (OAB) Therapeutics Historic Market Scenario in US$ Million by Drug Class: 2009-2017

TABLE 78: Brazilian Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

MEXICO

TABLE 79: Overactive Bladder (OAB) Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 80: Mexican Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 81: Mexican Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 82: Rest of Latin America Overactive Bladder (OAB) Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 83: Overactive Bladder (OAB) Therapeutics Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 84: Rest of Latin America Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 85: The Middle East Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 86: Overactive Bladder (OAB) Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017

TABLE 87: The Middle East Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 88: The Middle East Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025

TABLE 89: The Middle East Overactive Bladder (OAB) Therapeutics Historic Market by Drug Class in US$ Million: 2009-2017

TABLE 90: Overactive Bladder (OAB) Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025

IRAN

TABLE 91: Iranian Market for Overactive Bladder (OAB) Therapeutics: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025

TABLE 92: Overactive Bladder (OAB) Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017

TABLE 93: Iranian Overactive Bladder (OAB) Therapeutics Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025

ISRAEL

TABLE 94: Israeli Overactive Bladder (OAB) Therapeutics Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025

TABLE 95: Overactive Bladder (OAB) Therapeutics Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017

TABLE 96: Israeli Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 97: Saudi Arabian Overactive Bladder (OAB) Therapeutics Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025

TABLE 98: Overactive Bladder (OAB) Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017

TABLE 99: Saudi Arabian Overactive Bladder (OAB) Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 100: Overactive Bladder (OAB) Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 101: United Arab Emirates Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 102: Overactive Bladder (OAB) Therapeutics Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 103: Overactive Bladder (OAB) Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025

TABLE 104: Rest of Middle East Overactive Bladder (OAB) Therapeutics Historic Market Analysis in US$ Million by Drug Class: 2009-2017

TABLE 105: Rest of Middle East Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

AFRICA

TABLE 106: African Overactive Bladder (OAB) Therapeutics Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025

TABLE 107: Overactive Bladder (OAB) Therapeutics Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017

TABLE 108: African Overactive Bladder (OAB) Therapeutics Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025

IV. COMPETITION

ALLERGAN PLC

ASTELLAS PHARMA, INC.

HISAMITSU PHARMACEUTICAL CO., INC.

PFIZER, INC

DR. REDDY'S LABORATORIES LTD.

ELI LILLY AND COMPANY

ENDO PHARMACEUTICALS

NOVARTIS PHARMACEUTICALS CORPORATION

RECORDATI SPA

SPECIALITY EUROPEAN PHARMA

SUNOVION PHARMACEUTICALS, INC.

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan Plc
  • Astellas Pharma, Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Pfizer, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Novartis Pharmaceuticals Corporation
  • Recordati Spa
  • Speciality European Pharma
  • Sunovion Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll